Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index.

Coats S, Williams M, Kebble B, Dixit R, Tseng L, Yao NS, Tice DA, Soria JC.

Clin Cancer Res. 2019 Sep 15;25(18):5441-5448. doi: 10.1158/1078-0432.CCR-19-0272. Epub 2019 Apr 12. Review.

PMID:
30979742
2.

MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.

Greer YE, Gilbert SF, Gril B, Narwal R, Peacock Brooks DL, Tice DA, Steeg PS, Lipkowitz S.

Breast Cancer Res. 2019 Feb 18;21(1):27. doi: 10.1186/s13058-019-1116-1.

3.

Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition.

Zhong H, Chen C, Tammali R, Breen S, Zhang J, Fazenbaker C, Kennedy M, Conway J, Higgs BW, Holoweckyj N, Raja R, Harper J, Pierce AJ, Herbst R, Tice DA.

Mol Cancer Ther. 2019 Jan;18(1):89-99. doi: 10.1158/1535-7163.MCT-18-0314. Epub 2018 Oct 23.

PMID:
30352801
4.

Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells.

Kinneer K, Flynn M, Thomas SB, Meekin J, Varkey R, Xiao X, Zhong H, Breen S, Hynes PG, Fleming R, Bezabeh B, Chen CT, Wetzel L, Chen R, Dimasi N, Tai YT, Anderson KC, Herbst R, Howard PW, Hurt EM, Tice DA.

Leukemia. 2019 Mar;33(3):766-771. doi: 10.1038/s41375-018-0278-7. Epub 2018 Oct 12. No abstract available.

PMID:
30315237
5.

SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.

Kinneer K, Meekin J, Tiberghien AC, Tai YT, Phipps S, Kiefer CM, Rebelatto MC, Dimasi N, Moriarty A, Papadopoulos KP, Sridhar S, Gregson SJ, Wick MJ, Masterson L, Anderson KC, Herbst R, Howard PW, Tice DA.

Clin Cancer Res. 2018 Dec 15;24(24):6570-6582. doi: 10.1158/1078-0432.CCR-18-1300. Epub 2018 Aug 21.

PMID:
30131388
6.

Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.

Cho S, Zammarchi F, Williams DG, Havenith CEG, Monks NR, Tyrer P, D'Hooge F, Fleming R, Vashisht K, Dimasi N, Bertelli F, Corbett S, Adams L, Reinert HW, Dissanayake S, Britten CE, King W, Dacosta K, Tammali R, Schifferli K, Strout P, Korade M 3rd, Masson Hinrichs MJ, Chivers S, Corey E, Liu H, Kim S, Bander NH, Howard PW, Hartley JA, Coats S, Tice DA, Herbst R, van Berkel PH.

Mol Cancer Ther. 2018 Oct;17(10):2176-2186. doi: 10.1158/1535-7163.MCT-17-0982. Epub 2018 Jul 31.

7.

Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer.

Bosco EE, Christie RJ, Carrasco R, Sabol D, Zha J, DaCosta K, Brown L, Kennedy M, Meekin J, Phipps S, Ayriss J, Du Q, Bezabeh B, Chowdhury P, Breen S, Chen C, Reed M, Hinrichs M, Zhong H, Xiao Z, Dixit R, Herbst R, Tice DA.

Oncotarget. 2018 May 1;9(33):22960-22975. doi: 10.18632/oncotarget.25160. eCollection 2018 May 1.

8.

Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.

Kolluri KK, Alifrangis C, Kumar N, Ishii Y, Price S, Michaut M, Williams S, Barthorpe S, Lightfoot H, Busacca S, Sharkey A, Yuan Z, Sage EK, Vallath S, Le Quesne J, Tice DA, Alrifai D, von Karstedt S, Montinaro A, Guppy N, Waller DA, Nakas A, Good R, Holmes A, Walczak H, Fennell DA, Garnett M, Iorio F, Wessels L, McDermott U, Janes SM.

Elife. 2018 Jan 18;7. pii: e30224. doi: 10.7554/eLife.30224.

9.

Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.

Harper J, Lloyd C, Dimasi N, Toader D, Marwood R, Lewis L, Bannister D, Jovanovic J, Fleming R, D'Hooge F, Mao S, Marrero AM, Korade M 3rd, Strout P, Xu L, Chen C, Wetzel L, Breen S, van Vlerken-Ysla L, Jalla S, Rebelatto M, Zhong H, Hurt EM, Hinrichs MJ, Huang K, Howard PW, Tice DA, Hollingsworth RE, Herbst R, Kamal A.

Mol Cancer Ther. 2017 Aug;16(8):1576-1587. doi: 10.1158/1535-7163.MCT-16-0825. Epub 2017 May 18.

10.

5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma.

Kerk SA, Finkel KA, Pearson AT, Warner KA, Zhang Z, Nör F, Wagner VP, Vargas PA, Wicha MS, Hurt EM, Hollingsworth RE, Tice DA, Nör JE.

Clin Cancer Res. 2017 May 15;23(10):2516-2527. doi: 10.1158/1078-0432.CCR-16-1834. Epub 2016 Oct 25.

11.

IL-6 Inhibition With MEDI5117 Decreases The Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence.

Finkel KA, Warner KA, Kerk S, Bradford CR, McLean SA, Prince ME, Zhong H, Hurt EM, Hollingsworth RE, Wicha MS, Tice DA, Nör JE.

Neoplasia. 2016 May;18(5):273-281. doi: 10.1016/j.neo.2016.03.004. Epub 2016 Apr 15.

12.

A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.

Xiao Z, Carrasco RA, Schifferli K, Kinneer K, Tammali R, Chen H, Rothstein R, Wetzel L, Yang C, Chowdhury P, Tsui P, Steiner P, Jallal B, Herbst R, Hollingsworth RE, Tice DA.

Mol Cancer Ther. 2016 Apr;15(4):689-701. doi: 10.1158/1535-7163.MCT-15-0555. Epub 2016 Feb 15.

13.

A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.

Zhong H, Davis A, Ouzounova M, Carrasco RA, Chen C, Breen S, Chang YS, Huang J, Liu Z, Yao Y, Hurt E, Moisan J, Fung M, Tice DA, Clouthier SG, Xiao Z, Wicha MS, Korkaya H, Hollingsworth RE.

Cancer Res. 2016 Jan 15;76(2):480-90. doi: 10.1158/0008-5472.CAN-15-0883. Epub 2016 Jan 7.

14.

HER2 drives Mucin-like 1 to control proliferation in breast cancer cells.

Conley SJ, Bosco EE, Tice DA, Hollingsworth RE, Herbst R, Xiao Z.

Oncogene. 2016 Aug 11;35(32):4225-34. doi: 10.1038/onc.2015.487. Epub 2016 Jan 4.

15.

In Vivo Loss of Function Screening Reveals Carbonic Anhydrase IX as a Key Modulator of Tumor Initiating Potential in Primary Pancreatic Tumors.

Pore N, Jalla S, Liu Z, Higgs B, Sorio C, Scarpa A, Hollingsworth R, Tice DA, Michelotti E.

Neoplasia. 2015 Jun;17(6):473-80. doi: 10.1016/j.neo.2015.05.001.

16.

A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways.

Rios-Doria J, Sabol D, Chesebrough J, Stewart D, Xu L, Tammali R, Cheng L, Du Q, Schifferli K, Rothstein R, Leow CC, Heidbrink-Thompson J, Jin X, Gao C, Friedman J, Wilkinson B, Damschroder M, Pierce AJ, Hollingsworth RE, Tice DA, Michelotti EF.

Mol Cancer Ther. 2015 Jul;14(7):1637-49. doi: 10.1158/1535-7163.MCT-14-1040. Epub 2015 May 6.

17.

Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression.

Sungalee S, Mamessier E, Morgado E, Grégoire E, Brohawn PZ, Morehouse CA, Jouve N, Monvoisin C, Menard C, Debroas G, Faroudi M, Mechin V, Navarro JM, Drevet C, Eberle FC, Chasson L, Baudimont F, Mancini SJ, Tellier J, Picquenot JM, Kelly R, Vineis P, Ruminy P, Chetaille B, Jaffe ES, Schiff C, Hardwigsen J, Tice DA, Higgs BW, Tarte K, Nadel B, Roulland S.

J Clin Invest. 2014 Dec;124(12):5337-51. doi: 10.1172/JCI72415. Epub 2014 Nov 10.

18.

Multivalent scaffold proteins as superagonists of TRAIL receptor 2-induced apoptosis.

Swers JS, Grinberg L, Wang L, Feng H, Lekstrom K, Carrasco R, Xiao Z, Inigo I, Leow CC, Wu H, Tice DA, Baca M.

Mol Cancer Ther. 2013 Jul;12(7):1235-44. doi: 10.1158/1535-7163.MCT-12-1107. Epub 2013 May 3.

19.

EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: Implications for EphB4 as a cancer target.

Xiao Z, Carrasco R, Kinneer K, Sabol D, Jallal B, Coats S, Tice DA.

Cancer Biol Ther. 2012 Jun;13(8):630-7. doi: 10.4161/cbt.20080. Epub 2012 Jun 1.

PMID:
22555806
20.

A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth.

Streicher KL, Zhu W, Lehmann KP, Georgantas RW, Morehouse CA, Brohawn P, Carrasco RA, Xiao Z, Tice DA, Higgs BW, Richman L, Jallal B, Ranade K, Yao Y.

Oncogene. 2012 Mar 22;31(12):1558-70. doi: 10.1038/onc.2011.345. Epub 2011 Aug 22.

PMID:
21860416
21.

Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.

Yang NY, Fernandez C, Richter M, Xiao Z, Valencia F, Tice DA, Pasquale EB.

Cell Signal. 2011 Jan;23(1):201-12. doi: 10.1016/j.cellsig.2010.09.004. Epub 2010 Sep 15.

22.

Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma.

Moschos SJ, Sander CA, Wang W, Reppert SL, Drogowski LM, Jukic DM, Rao UN, Athanassiou C, Buzoianu M, Mandic M, Richman L, McKinney L, Leininger J, Tice DA, Hammershaimb L, Kirkwood JM.

J Immunother. 2010 Apr;33(3):316-25. doi: 10.1097/CJI.0b013e3181c1f216.

PMID:
20445352
23.

Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.

Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings NB, Coleman RL, Tice DA, Sood AK.

Cancer Biol Ther. 2009 Dec;8(23):2263-72. Epub 2009 Dec 19.

24.

EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.

Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK.

J Natl Cancer Inst. 2009 Sep 2;101(17):1193-205. doi: 10.1093/jnci/djp231. Epub 2009 Jul 29.

25.

A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo.

Jackson D, Gooya J, Mao S, Kinneer K, Xu L, Camara M, Fazenbaker C, Fleming R, Swamynathan S, Meyer D, Senter PD, Gao C, Wu H, Kinch M, Coats S, Kiener PA, Tice DA.

Cancer Res. 2008 Nov 15;68(22):9367-74. doi: 10.1158/0008-5472.CAN-08-1933.

26.

Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice.

Cai W, Ebrahimnejad A, Chen K, Cao Q, Li ZB, Tice DA, Chen X.

Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):2024-36. Epub 2007 Aug 3.

PMID:
17673999
27.

Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin.

Mulgrew K, Kinneer K, Yao XT, Ward BK, Damschroder MM, Walsh B, Mao SY, Gao C, Kiener PA, Coats S, Kinch MS, Tice DA.

Mol Cancer Ther. 2006 Dec;5(12):3122-9.

28.
29.

The C terminus of c-Src inhibits breast tumor cell growth by a kinase-independent mechanism.

Ishizawar RC, Tice DA, Karaoli T, Parsons SJ.

J Biol Chem. 2004 May 28;279(22):23773-81. Epub 2004 Mar 18.

30.

Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling.

Tice DA, Szeto W, Soloviev I, Rubinfeld B, Fong SE, Dugger DL, Winer J, Williams PM, Wieand D, Smith V, Schwall RH, Pennica D, Polakis P.

J Biol Chem. 2002 Apr 19;277(16):14329-35. Epub 2002 Feb 6.

31.

Activation of the Wnt pathway interferes with serum response element-driven transcription of immediate early genes.

Tice DA, Soloviev I, Polakis P.

J Biol Chem. 2002 Feb 22;277(8):6118-23. Epub 2001 Dec 18.

32.

Axin-dependent phosphorylation of the adenomatous polyposis coli protein mediated by casein kinase 1epsilon.

Rubinfeld B, Tice DA, Polakis P.

J Biol Chem. 2001 Oct 19;276(42):39037-45. Epub 2001 Aug 3.

33.

Overexpression of the retinoic acid-responsive gene Stra6 in human cancers and its synergistic induction by Wnt-1 and retinoic acid.

Szeto W, Jiang W, Tice DA, Rubinfeld B, Hollingshead PG, Fong SE, Dugger DL, Pham T, Yansura DG, Wong TA, Grimaldi JC, Corpuz RT, Singh JS, Frantz GD, Devaux B, Crowley CW, Schwall RH, Eberhard DA, Rastelli L, Polakis P, Pennica D.

Cancer Res. 2001 May 15;61(10):4197-205.

34.

Src family kinases and HER2 interactions in human breast cancer cell growth and survival.

Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA, Parsons SJ.

Oncogene. 2001 Mar 22;20(12):1465-75.

35.

c-Src, receptor tyrosine kinases, and human cancer.

Biscardi JS, Tice DA, Parsons SJ.

Adv Cancer Res. 1999;76:61-119. Review. No abstract available.

PMID:
10218099
36.
37.

Mechanism of biological synergy between cellular Src and epidermal growth factor receptor.

Tice DA, Biscardi JS, Nickles AL, Parsons SJ.

Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1415-20.

38.

Overexpression of cellular Src in fibroblasts enhances endocytic internalization of epidermal growth factor receptor.

Ware MF, Tice DA, Parsons SJ, Lauffenburger DA.

J Biol Chem. 1997 Nov 28;272(48):30185-90.

39.

Misplaced Greenfield filter: diagnosis by transesophageal echocardiography.

Dorsa FB, Gindea AJ, Kralik M, Tice DA.

J Am Soc Echocardiogr. 1992 Jul-Aug;5(4):437-8.

PMID:
1510860
40.

Repair of thoracic aortic aneurysms in the elderly: are shunts necessary?

Tice DA.

J Vasc Surg. 1988 Jul;8(1):92-3. No abstract available.

PMID:
3385887
41.

Ischemic optic neuropathy and cardiac surgery.

Tice DA.

Ann Thorac Surg. 1987 Dec;44(6):677. No abstract available.

PMID:
3500683
42.
43.
44.

Infective endocarditis. An analysis of 54 surgically treated patients.

Boyd AD, Spencer FC, Isom OW, Cunningham JN, Reed GE, Acinapura AJ, Tice DA.

J Thorac Cardiovasc Surg. 1977 Jan;73(1):23-30.

PMID:
831008
45.

Low dosage of heparin.

Tice DA.

Surg Gynecol Obstet. 1976 Dec;143(6):970-1. No abstract available.

PMID:
996718
46.

Operative risk in patients with previous coronary artery bypass.

Scher KS, Tice DA.

Arch Surg. 1976 Jul;111(7):807-9.

PMID:
1084739
47.

The effects of excision of left ventricular scars on the electrocardiogram.

Dolgin M, Fisher VJ, Shah A, Tice DA, Fisher B.

Am J Med Sci. 1976 May-Jun;271(3):277-83.

PMID:
937378
48.

Coronary artery bypass with freeze-preserved saphenous vein allografts.

Tice DA, Zerbino VR, Isom OW, Cunningham JN, Engelman RM.

J Thorac Cardiovasc Surg. 1976 Mar;71(3):378-82.

PMID:
1082533
49.

Esophagogastrostomy. Analysis of 55 cases.

Boyd AD, Cukingnan R, Engelman RM, Localio SA, Slattery L, Tice DA, Bardin JA, Spencer FC.

J Thorac Cardiovasc Surg. 1975 Nov;70(5):817-25.

PMID:
1186273
50.

Clinical vs hemodynamic classification of cirrhosis.

Kessler RE, Tice DA, Solowey AC, Zimmon DS.

Surg Forum. 1975;26:417-9. No abstract available.

PMID:
1216182

Supplemental Content

Support Center